Case Type: Mergers & Acquisitions

Arconic Corp. (NYSE: ARNC), relating to its proposed sale to affiliates of Apollo Global Management, Inc. Under the terms of the agreement, ARNC shareholders are expected to receive $30.00 in cash per share they own.

Enzo Biochem, Inc. (NYSE: ENZ), relating to its proposed sale to Laboratory Corporation of America Holdings.

Ruth’s Hospitality Group, Inc. (NASDAQ: RUTH), relating to its proposed sale to Darden Restaurants, Inc. Under the terms of the tender offer, RUTH shareholders are expected to receive $21.50 in cash per share they own.

Midwest Holding Inc. (NASDAQ: MDWT), relating to its proposed sale to Antarctica Capital. Under the terms of the agreement, MDWT shareholders are expected to receive $27.00 in cash per share they own.

IVERIC bio, Inc. (NASDAQ: ISEE), relating to its proposed sale to Astellas Pharma Inc. Under the terms of the agreement, ISEE shareholders are expected to receive $40.00 in cash per share they own.

Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), relating to its proposed sale to Assertio Holdings, Inc. Under the terms of the agreement, SPPI shareholders are expected to receive 0.1783 shares of Assertio common stock and one CVR worth up to $0.20, based upon the 2024 and 2025 net sales of ROLVEDON, per share they own.

Muncy Bank Financial, Inc. (OTC: MYBF), relating to its proposed acquisition by CCFNB Bancorp, Inc. Under the terms of the agreement, MYBF shareholders are expected to receive 0.9259 shares of CCFNB per share they own.

Triton International Ltd. (NYSE: TRTN), relating to its proposed sale to Brookfield Infrastructure Partners, L.P.

Prometheus Biosciences, Inc. (NASDAQ: RXDX), relating to its proposed sale to Merck and Co. Under the terms of the agreement, RXDX shareholders are expected to receive $200.00 in cash per share they own.

Satsuma Pharmaceuticals, Inc. (NASDAQ: STSA), relating to its proposed sale to Shin Nippon Biomedical Laboratories, Ltd. Under the terms of the agreement, STSA Shareholders are expected to receive one non-tradeable CVR of up to $5.77 in cash plus $0.91 in cash per share they own.